score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.429						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (43%)		Osteosarcoma-IVSS621		
Biologically Relevant				Somatic Variant	POT1	Splice Site		0.0423	71.0	0.0	0.0																					0	0.0	0.0	0.0	POT1  (Splice Site)		Osteosarcoma-IVSS621	Osteosarcoma-IVSS621-Tumor-SM-2RCB4	Osteosarcoma-IVSS621-Normal-SM-2RCCJ
Biologically Relevant				Copy Number	MPL	Amplification				0.0	0.0																					0				MPL Amplification		Osteosarcoma-IVSS621	IVSS621_T	
Biologically Relevant				Mutational Signature	COSMIC Signature 30	version 2	0.25																									0				COSMIC Signature (version 2) 30 (25%)		Osteosarcoma-IVSS621		
